Skip To Main Content

This website is intended exclusively for healthcare professionals residing and/or working in Bahrain.

Campus

Login
Registration

Science
Acquired Thrombotic Thrombocytopenic Purpura (ATTP)
Anti-Infectives
Asthma
Chronic Obstructive Pulmonary Disease
Eosinophilic-Esophagitis
Multiple Myeloma
Nasal Polyps
Neurological Disorders
Prurigo-Nodularis
Rare Diseases

Atopic Dermatitis

Cutting Edge Science
Innovation

Cardiovascular
Atherothrombosis
Dyslipidemia
Hypertension
Thrombosis

Diabetes
Cutting Edge Science

Multiple Sclerosis

Cutting Edge Science
Innovation
2024

Vaccines
Influenza
Meningitis
Pertussis & Polio
RSV

Patient Support
Atopic Dermatitis
Cardiovascular
Diabetes
Rare Diseases

Products
Adacel®
Cerezyme®
Lemtrada®
Myozyme®
Renvela®
Tavanic®
Xatral®

Aubagio®
Aubagio vs Ofatumumab

Clexane®
Surgical Patients
Hemodialysis

Dupixent®
Atopic Dermatitis

Fabrazyme®
Quantifying the Effect of Fabrazyme
Canadian Fabry Disease Initiative
Long Term Renal Function

Plavix®
Tolerability

Praluent®

It’s Praluent of Course
MACE Reduction
Mortality Reduction
Patient Friendly
Ticks All the Boxes

Soliqua®
For a Peaceful Ramadan
Soli-Simplify Study
Soliqua SoliD®
Soliqua Easy Start®
Soliqua Guidelines®
Soliqua Data Set®
Soliqua Simplicity®
Soliqua Safety®
Soliqua®

Toujeo®
Toujeo for a Peaceful Ramadan
Wall of Evidence
How to Start

Toujeo T1DM
OneCare
Edition Junior
UltraFlexi-1
Type-1 Meta Analysis
Guidelines

Toujeo T2DM
Deliver-G
Guidelines

Toujeo Innovation
Toujeo Upgrade to Win

Campus

Science
Acquired Thrombotic Thrombocytopenic Purpura (ATTP)
Anti-Infectives
Asthma
Chronic Obstructive Pulmonary Disease
Eosinophilic-Esophagitis
Multiple Myeloma
Nasal Polyps
Neurological Disorders
Prurigo-Nodularis
Rare Diseases

Atopic Dermatitis

Cutting Edge Science
Innovation

Cardiovascular
Atherothrombosis
Dyslipidemia
Hypertension
Thrombosis

Diabetes
Cutting Edge Science

Multiple Sclerosis

Cutting Edge Science
Innovation
2024

Vaccines
Influenza
Meningitis
Pertussis & Polio
RSV

Patient Support
Atopic Dermatitis
Cardiovascular
Diabetes
Rare Diseases

Products
Adacel®
Cerezyme®
Lemtrada®
Myozyme®
Renvela®
Tavanic®
Xatral®

Aubagio®
Aubagio vs Ofatumumab

Clexane®
Surgical Patients
Hemodialysis

Dupixent®
Atopic Dermatitis

Fabrazyme®
Quantifying the Effect of Fabrazyme
Canadian Fabry Disease Initiative
Long Term Renal Function

Plavix®
Tolerability

Praluent®

It’s Praluent of Course
MACE Reduction
Mortality Reduction
Patient Friendly
Ticks All the Boxes

Soliqua®
For a Peaceful Ramadan
Soli-Simplify Study
Soliqua SoliD®
Soliqua Easy Start®
Soliqua Guidelines®
Soliqua Data Set®
Soliqua Simplicity®
Soliqua Safety®
Soliqua®

Toujeo®
Toujeo for a Peaceful Ramadan
Wall of Evidence
How to Start

Toujeo T1DM
OneCare
Edition Junior
UltraFlexi-1
Type-1 Meta Analysis
Guidelines

Toujeo T2DM
Deliver-G
Guidelines

Toujeo Innovation
Toujeo Upgrade to Win

Login
Registration

Cardio-Risk app

MAT-BH-2300530

Campus

Back to top

Legal notice Cookie policy Privacy policy Sitemap Change country

© Sanofi 2004- - All rights reserved

MAT-BH-2100734/V7/MAR2024

SANOFI, Level 3, One JLT, Jumeirah Lake Towers (JLT), DMCC, PO Box 53899, Dubai, UAE,

Tel.: +971 4 550 3600 | Fax: +971 4 5521050

For further medical information for all Gulf countries, please contact: +971 45 50 38 63
or email: medical-information.gulf@sanofi.com

To report an adverse event: please call: +971 561747001 or Email: Gulf.pharmacovigilance@sanofi.com
To report any product technical complaints, kindly contact Email: quality.greatergulf@sanofi.com

leave-site-modal-text

YOU WILL NOW BE LEAVING THE SITE

By clicking on this link, you will be leaving the Campus Sanofi website and going to another, entirely independent website.
Please note: Sanofi provides these links as a service to its website visitors and users; however, Sanofi takes no responsibility for the information on any website but its own.